Matches in SemOpenAlex for { <https://semopenalex.org/work/W2970403714> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2970403714 endingPage "1235" @default.
- W2970403714 startingPage "1229" @default.
- W2970403714 abstract "Background. Subcutaneous methotrexate (sMTX) administration is considered more effective than the oral route due to better bioavailability and a lower rate of adverse drug reactions (ADRs); however, clinical data supporting this hypothesis is scarce.Objectives. The aim of the study was to evaluate the efficacy and tolerability of sMTX in patients with active rheumatoid arthritis (RA), including a subset classified as an early stage of RA.Material and Methods. A post-marketing, multicenter, open-label, non-randomized, non-interventional study enrolled 771 adult patients with active RA treated with sMTX (Metex®) for 2–6 weeks. The evaluation of therapy effectiveness (DAS28-ESR or DAS28-CRP) and monitoring of ADRs was an element of routine patient management. Therapy effectiveness was scored as the achievement of remission or response (according to European League Against Rheumatism (EULAR)).Results. Among 761 (98.7%) patients that continued sMTX (after 25–31 weeks), clinical response was achieved by 69.5%, remission by 19.2% and low disease activity by 34.2%. Patients aged >60 years were less likely to achieve both remission (odds ratio (OR) = 0.61 (95% confidence interval (95% CI) = 0.39–0.93)) and clinical response (OR = 0.82 (95% CI = 0.71–0.95)), while overweight/obese patients (OR = 1.11 (95% CI = 1.00–1.24)) and those with early RA had greater chance to reach a clinical response (OR = 1.18 (95% CI = 1.03–1.34)). There were 16 ADRs (no serious or severe). In addition, at least 2-fold increase in alanine transaminase (ALT) activity was noted in 10 patients (1.3%).Conclusion. After 6-month therapy with sMTX, about 70% of patients with RA achieve a clinical response, and remission was observed in 20%. Younger age, overweight/obesity and an early stage of the disease are factors increasing therapy effectiveness; sMTX is well tolerated." @default.
- W2970403714 created "2019-09-05" @default.
- W2970403714 creator A5012015082 @default.
- W2970403714 creator A5020061892 @default.
- W2970403714 creator A5034608645 @default.
- W2970403714 creator A5041297167 @default.
- W2970403714 creator A5045517198 @default.
- W2970403714 creator A5087742680 @default.
- W2970403714 date "2019-08-22" @default.
- W2970403714 modified "2023-10-16" @default.
- W2970403714 title "Effectiveness of subcutaneously administered methotrexate in patients with rheumatoid arthritis" @default.
- W2970403714 doi "https://doi.org/10.17219/acem/105379" @default.
- W2970403714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31464109" @default.
- W2970403714 hasPublicationYear "2019" @default.
- W2970403714 type Work @default.
- W2970403714 sameAs 2970403714 @default.
- W2970403714 citedByCount "3" @default.
- W2970403714 countsByYear W29704037142021 @default.
- W2970403714 countsByYear W29704037142022 @default.
- W2970403714 countsByYear W29704037142023 @default.
- W2970403714 crossrefType "journal-article" @default.
- W2970403714 hasAuthorship W2970403714A5012015082 @default.
- W2970403714 hasAuthorship W2970403714A5020061892 @default.
- W2970403714 hasAuthorship W2970403714A5034608645 @default.
- W2970403714 hasAuthorship W2970403714A5041297167 @default.
- W2970403714 hasAuthorship W2970403714A5045517198 @default.
- W2970403714 hasAuthorship W2970403714A5087742680 @default.
- W2970403714 hasBestOaLocation W29704037141 @default.
- W2970403714 hasConcept C126322002 @default.
- W2970403714 hasConcept C141071460 @default.
- W2970403714 hasConcept C156957248 @default.
- W2970403714 hasConcept C197934379 @default.
- W2970403714 hasConcept C2777489490 @default.
- W2970403714 hasConcept C2777575956 @default.
- W2970403714 hasConcept C2778375690 @default.
- W2970403714 hasConcept C2781059491 @default.
- W2970403714 hasConcept C44249647 @default.
- W2970403714 hasConcept C71924100 @default.
- W2970403714 hasConcept C90924648 @default.
- W2970403714 hasConceptScore W2970403714C126322002 @default.
- W2970403714 hasConceptScore W2970403714C141071460 @default.
- W2970403714 hasConceptScore W2970403714C156957248 @default.
- W2970403714 hasConceptScore W2970403714C197934379 @default.
- W2970403714 hasConceptScore W2970403714C2777489490 @default.
- W2970403714 hasConceptScore W2970403714C2777575956 @default.
- W2970403714 hasConceptScore W2970403714C2778375690 @default.
- W2970403714 hasConceptScore W2970403714C2781059491 @default.
- W2970403714 hasConceptScore W2970403714C44249647 @default.
- W2970403714 hasConceptScore W2970403714C71924100 @default.
- W2970403714 hasConceptScore W2970403714C90924648 @default.
- W2970403714 hasIssue "9" @default.
- W2970403714 hasLocation W29704037141 @default.
- W2970403714 hasLocation W29704037142 @default.
- W2970403714 hasOpenAccess W2970403714 @default.
- W2970403714 hasPrimaryLocation W29704037141 @default.
- W2970403714 hasRelatedWork W2100063456 @default.
- W2970403714 hasRelatedWork W2315214631 @default.
- W2970403714 hasRelatedWork W2353466245 @default.
- W2970403714 hasRelatedWork W2417665825 @default.
- W2970403714 hasRelatedWork W2508614712 @default.
- W2970403714 hasRelatedWork W4210973548 @default.
- W2970403714 hasRelatedWork W4294301186 @default.
- W2970403714 hasRelatedWork W71234347 @default.
- W2970403714 hasRelatedWork W2185841895 @default.
- W2970403714 hasRelatedWork W2625400488 @default.
- W2970403714 hasVolume "28" @default.
- W2970403714 isParatext "false" @default.
- W2970403714 isRetracted "false" @default.
- W2970403714 magId "2970403714" @default.
- W2970403714 workType "article" @default.